Stephen Willey
Stock Analyst at Stifel
(4.19)
# 767
Out of 5,182 analysts
134
Total ratings
48.48%
Success rate
16.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Buy | $115 → $125 | $125.68 | -0.54% | 3 | Mar 26, 2026 | |
| INSM Insmed | Maintains: Buy | $205 → $208 | $135.98 | +52.96% | 9 | Mar 24, 2026 | |
| ZYME Zymeworks | Maintains: Buy | $40 → $47 | $28.56 | +64.57% | 8 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Hold | $127 → $115 | $115.07 | -0.06% | 2 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $68.85 | +59.77% | 2 | Feb 17, 2026 | |
| INCY Incyte | Maintains: Buy | $119 → $120 | $95.72 | +25.37% | 8 | Feb 11, 2026 | |
| EXEL Exelixis | Maintains: Hold | $43 → $44 | $44.65 | -1.46% | 20 | Feb 11, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $16.49 | +112.25% | 6 | Jan 29, 2026 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.83 | +288.69% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $4.21 | +113.78% | 3 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $4.16 | +68.27% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $25.15 | +11.33% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $3.05 | +63.93% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.96 | +303.23% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.12 | +608.22% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.53 | +161.44% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $22.48 | +109.12% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $120 | $17.93 | +569.27% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.92 | +36.99% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $54.26 | +14.26% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.79 | +402.79% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.44 | +733.33% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.17 | +24,515.38% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.67 | +686.52% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.69 | +136.69% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $308.51 | -60.13% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $72.23 | -34.93% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $53.81 | +102.58% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $23.36 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.97 | +188.58% | 5 | Feb 7, 2018 |
Celcuity
Mar 26, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $125.68
Upside: -0.54%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $205 → $208
Current: $135.98
Upside: +52.96%
Zymeworks
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $47
Current: $28.56
Upside: +64.57%
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $127 → $115
Current: $115.07
Upside: -0.06%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $68.85
Upside: +59.77%
Incyte
Feb 11, 2026
Maintains: Buy
Price Target: $119 → $120
Current: $95.72
Upside: +25.37%
Exelixis
Feb 11, 2026
Maintains: Hold
Price Target: $43 → $44
Current: $44.65
Upside: -1.46%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $16.49
Upside: +112.25%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.83
Upside: +288.69%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $4.21
Upside: +113.78%
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.16
Upside: +68.27%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $25.15
Upside: +11.33%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $3.05
Upside: +63.93%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.96
Upside: +303.23%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $14.12
Upside: +608.22%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.53
Upside: +161.44%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $22.48
Upside: +109.12%
Aug 20, 2024
Maintains: Buy
Price Target: $240 → $120
Current: $17.93
Upside: +569.27%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.92
Upside: +36.99%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $54.26
Upside: +14.26%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $1.79
Upside: +402.79%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.44
Upside: +733.33%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.17
Upside: +24,515.38%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.67
Upside: +686.52%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.69
Upside: +136.69%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $308.51
Upside: -60.13%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $72.23
Upside: -34.93%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $53.81
Upside: +102.58%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $23.36
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.97
Upside: +188.58%